Context:
Financial Statements:
| Column 1                                                                                             | Column 2   | Column 3           | Column 4   | Column 5          | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   |
|:-----------------------------------------------------------------------------------------------------|:-----------|:-------------------|:-----------|:------------------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                                                                      |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
|                                                                                                      |            | September 27, 2020 |            | December 29, 2019 |            |            |            |            |             |             |             |             |             |             |
| ASSETS                                                                                               |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Current assets:                                                                                      |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Cash and cash equivalents                                                                            |            | $                  | 18,965     |                   |            | 17,305     |            |            |             |             |             |             |             |             |
| Marketable securities                                                                                |            | 11,816             |            |                   | 1,982      |            |            |            |             |             |             |             |             |             |
| Accounts receivable, trade, less allowances for doubtful accounts and credit losses $292(2019, $226) |            | 14,579             |            |                   | 14,481     |            |            |            |             |             |             |             |             |             |
| Inventories (Note 2)                                                                                 |            | 9,599              |            |                   | 9,020      |            |            |            |             |             |             |             |             |             |
| Prepaid expenses and other                                                                           |            | 2,528              |            |                   | 2,392      |            |            |            |             |             |             |             |             |             |
| Assets held for sale (Note 10)                                                                       |            | 91                 |            |                   | 94         |            |            |            |             |             |             |             |             |             |
| Total current assets                                                                                 |            | 57,578             |            |                   | 45,274     |            |            |            |             |             |             |             |             |             |
| Property, plant and equipment at cost                                                                |            | 45,162             |            |                   | 43,332     |            |            |            |             |             |             |             |             |             |
| Less: accumulated depreciation                                                                       |            | (27,307)           |            |                   | (25,674)   |            |            |            |             |             |             |             |             |             |
| Property, plant and equipment, net                                                                   |            | 17,855             |            |                   | 17,658     |            |            |            |             |             |             |             |             |             |
| Intangible assets, net (Note 3)                                                                      |            | 47,006             |            |                   | 47,643     |            |            |            |             |             |             |             |             |             |
| Goodwill (Note 3)                                                                                    |            | 34,307             |            |                   | 33,639     |            |            |            |             |             |             |             |             |             |
| Deferred taxes on income (Note 5)                                                                    |            | 7,816              |            |                   | 7,819      |            |            |            |             |             |             |             |             |             |
| Other assets                                                                                         |            | 6,131              |            |                   | 5,695      |            |            |            |             |             |             |             |             |             |
| Total assets                                                                                         |            | $                  | 170,693    |                   |            | 157,728    |            |            |             |             |             |             |             |             |
| LIABILITIES AND SHAREHOLDERS’ EQUITY                                                                 |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Current liabilities:                                                                                 |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Loans and notes payable                                                                              |            | $                  | 5,078      |                   |            | 1,202      |            |            |             |             |             |             |             |             |
| Accounts payable                                                                                     |            | 7,044              |            |                   | 8,544      |            |            |            |             |             |             |             |             |             |
| Accrued liabilities                                                                                  |            | 9,629              |            |                   | 9,715      |            |            |            |             |             |             |             |             |             |
| Accrued rebates, returns and promotions                                                              |            | 12,418             |            |                   | 10,883     |            |            |            |             |             |             |             |             |             |
| Accrued compensation and employee related obligations                                                |            | 3,012              |            |                   | 3,354      |            |            |            |             |             |             |             |             |             |
| Accrued taxes on income (Note 5)                                                                     |            | 1,666              |            |                   | 2,266      |            |            |            |             |             |             |             |             |             |
| Total current liabilities                                                                            |            | 38,847             |            |                   | 35,964     |            |            |            |             |             |             |             |             |             |
| Long-term debt (Note 4)                                                                              |            | 32,680             |            |                   | 26,494     |            |            |            |             |             |             |             |             |             |
| Deferred taxes on income(Note 5)                                                                     |            | 5,615              |            |                   | 5,958      |            |            |            |             |             |             |             |             |             |
| Employee related obligations (Note 6)                                                                |            | 10,184             |            |                   | 10,663     |            |            |            |             |             |             |             |             |             |
| Long-term taxes payable (Note 5)                                                                     |            | 6,745              |            |                   | 7,444      |            |            |            |             |             |             |             |             |             |
| Other liabilities                                                                                    |            | 12,149             |            |                   | 11,734     |            |            |            |             |             |             |             |             |             |
| Total liabilities                                                                                    |            | 106,220            |            |                   | 98,257     |            |            |            |             |             |             |             |             |             |
| Commitments and Contingencies (Note 11)                                                              |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Shareholders’ equity:                                                                                |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Common stock — par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares)   |            | $                  | 3,120      |                   |            | 3,120      |            |            |             |             |             |             |             |             |
| Accumulated other comprehensive income (loss) (Note 7)                                               |            | (14,938)           |            |                   | (15,891)   |            |            |            |             |             |             |             |             |             |
| Retained earnings                                                                                    |            | 114,831            |            |                   | 110,659    |            |            |            |             |             |             |             |             |             |
| Less: common stock held in treasury, at cost (487,676,000and487,336,000shares)                       |            | 38,540             |            |                   | 38,417     |            |            |            |             |             |             |             |             |             |
| Total shareholders’ equity                                                                           |            | 64,473             |            |                   | 59,471     |            |            |            |             |             |             |             |             |             |
| Total liabilities and shareholders' equity                                                           |            | $                  | 170,693    |                   |            | 157,728    |            |            |             |             |             |             |             |             |

---

| Column 1                                                                                  | Column 2   | Column 3                 | Column 4   | Column 5          | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   |
|:------------------------------------------------------------------------------------------|:-----------|:-------------------------|:-----------|:------------------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            | Fiscal Nine Months Ended |            |                   |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            | September 27,2020        |            | September 29,2019 |            |            |            |            |             |             |             |             |             |             |
| CASH FLOWS FROM OPERATING ACTIVITIES                                                      |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
| Net earnings                                                                              |            | $                        | 12,976     |                   |            | 11,109     |            |            |             |             |             |             |             |             |
| Adjustments to reconcile net earnings to cash flows from operating activities:            |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
| Depreciation and amortization of property and intangibles                                 |            | 5,291                    |            |                   | 5,193      |            |            |            |             |             |             |             |             |             |
| Stock based compensation                                                                  |            | 845                      |            |                   | 817        |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
| Asset write-downs                                                                         |            | 198                      |            |                   | 1,019      |            |            |            |             |             |             |             |             |             |
| Contingent consideration reversal                                                         |            | (1,148)                  |            |                   | —          |            |            |            |             |             |             |             |             |             |
| Net gain on sale of assets/businesses                                                     |            | (60)                     |            |                   | (2,125)    |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
| Deferred tax provision                                                                    |            | (238)                    |            |                   | (2,126)    |            |            |            |             |             |             |             |             |             |
| Credit losses and accounts receivable allowances                                          |            | 74                       |            |                   | (15)       |            |            |            |             |             |             |             |             |             |
| Changes in assets and liabilities, net of effects from acquisitions and divestitures:     |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
| Increase in accounts receivable                                                           |            | (440)                    |            |                   | (665)      |            |            |            |             |             |             |             |             |             |
| Increase in inventories                                                                   |            | (784)                    |            |                   | (424)      |            |            |            |             |             |             |             |             |             |
| (Decrease)/Increase in accounts payable and accrued liabilities                           |            | (119)                    |            |                   | 2,273      |            |            |            |             |             |             |             |             |             |
| Increase in other current and non-current assets                                          |            | (1,983)                  |            |                   | (81)       |            |            |            |             |             |             |             |             |             |
| Increase in other current and non-current liabilities                                     |            | 581                      |            |                   | 2,043      |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
| NET CASH FLOWS FROM OPERATING ACTIVITIES                                                  |            | 15,193                   |            |                   | 17,018     |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
| CASH FLOWS FROM INVESTING ACTIVITIES                                                      |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
| Additions to property, plant and equipment                                                |            | (2,024)                  |            |                   | (2,238)    |            |            |            |             |             |             |             |             |             |
| Proceeds from the disposal of assets/businesses, net                                      |            | 100                      |            |                   | 3,103      |            |            |            |             |             |             |             |             |             |
| Acquisitions, net of cash acquired                                                        |            | (949)                    |            |                   | (5,562)    |            |            |            |             |             |             |             |             |             |
| Purchases of investments                                                                  |            | (16,243)                 |            |                   | (2,684)    |            |            |            |             |             |             |             |             |             |
| Sales of investments                                                                      |            | 6,585                    |            |                   | 2,459      |            |            |            |             |             |             |             |             |             |
| Proceeds from credit support agreements, net                                              |            | 125                      |            |                   | —          |            |            |            |             |             |             |             |             |             |
| Other (primarily licenses and milestones)                                                 |            | (516)                    |            |                   | 72         |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
| NET CASH USED BY INVESTING ACTIVITIES                                                     |            | (12,922)                 |            |                   | (4,850)    |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
| CASH FLOWS FROM FINANCING ACTIVITIES                                                      |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
| Dividends to shareholders                                                                 |            | (7,823)                  |            |                   | (7,417)    |            |            |            |             |             |             |             |             |             |
| Repurchase of common stock                                                                |            | (2,900)                  |            |                   | (6,320)    |            |            |            |             |             |             |             |             |             |
| Proceeds from short-term debt                                                             |            | 3,335                    |            |                   | 148        |            |            |            |             |             |             |             |             |             |
| Repayment of short-term debt                                                              |            | (310)                    |            |                   | (87)       |            |            |            |             |             |             |             |             |             |
| Proceeds from long-term debt, net of issuance costs                                       |            | 7,431                    |            |                   | 1          |            |            |            |             |             |             |             |             |             |
| Repayment of long-term debt                                                               |            | (562)                    |            |                   | (1,008)    |            |            |            |             |             |             |             |             |             |
| Proceeds from the exercise of stock options/employee withholding tax on stock awards, net |            | 922                      |            |                   | 580        |            |            |            |             |             |             |             |             |             |
| Other                                                                                     |            | (569)                    |            |                   | 160        |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
| NET CASH USED BY FINANCING ACTIVITIES                                                     |            | (476)                    |            |                   | (13,943)   |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
| Effect of exchange rate changes on cash and cash equivalents                              |            | (135)                    |            |                   | (83)       |            |            |            |             |             |             |             |             |             |
| Increase/(Decrease) in cash and cash equivalents                                          |            | 1,660                    |            |                   | (1,858)    |            |            |            |             |             |             |             |             |             |
| Cash and Cash equivalents, beginning of period                                            |            | 17,305                   |            |                   | 18,107     |            |            |            |             |             |             |             |             |             |
| CASH AND CASH EQUIVALENTS, END OF PERIOD                                                  |            | $                        | 18,965     |                   |            | 16,249     |            |            |             |             |             |             |             |             |
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
| Acquisitions                                                                              |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
| Fair value of assets acquired                                                             |            | $                        | 1,173      |                   |            | 6,861      |            |            |             |             |             |             |             |             |
| Fair value of liabilities assumed and noncontrolling interests                            |            | (224)                    |            |                   | (1,299)    |            |            |            |             |             |             |             |             |             |
| Net cash paid for acquisitions                                                            |            | $                        | 949        |                   |            | 5,562      |            |            |             |             |             |             |             |             |
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |
|                                                                                           |            |                          |            |                   |            |            |            |            |             |             |             |             |             |             |

---

| Column 1                                              | Column 2   | Column 3                   | Column 4   | Column 5        | Column 6   | Column 7          | Column 8   | Column 9        | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   | Column 16   | Column 17   | Column 18   | Column 19   | Column 20   | Column 21   | Column 22   | Column 23   | Column 24   | Column 25   | Column 26   | Column 27   |
|:------------------------------------------------------|:-----------|:---------------------------|:-----------|:----------------|:-----------|:------------------|:-----------|:----------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                       |            |                            |            |                 |            |                   |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                       |            | Fiscal Third Quarter Ended |            |                 |            |                   |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                       |            | September 27,2020          |            | Percentto Sales |            | September 29,2019 |            | Percentto Sales |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Sales to customers (Note 9)                           |            | $                          | 21,082     |                 |            | 100.0             | %          |                 | $           | 20,729      |             |             | 100.0       | %           |             |             |             |             |             |             |             |             |             |             |             |             |
| Cost of products sold                                 |            | 6,972                      |            |                 | 33.1       |                   |            | 6,867           |             |             | 33.1        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Gross profit                                          |            | 14,110                     |            |                 | 66.9       |                   |            | 13,862          |             |             | 66.9        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Selling, marketing and administrative expenses        |            | 5,431                      |            |                 | 25.8       |                   |            | 5,374           |             |             | 26.0        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Research and development expense                      |            | 2,840                      |            |                 | 13.5       |                   |            | 2,599           |             |             | 12.5        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| In-process research and development                   |            | 138                        |            |                 | 0.6        |                   |            | —               |             |             | —           |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Interest income                                       |            | (12)                       |            |                 | (0.1)      |                   |            | (89)            |             |             | (0.4)       |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Interest expense, net of portion capitalized          |            | 44                         |            |                 | 0.2        |                   |            | 48              |             |             | 0.2         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Other (income) expense, net                           |            | 1,200                      |            |                 | 5.7        |                   |            | 4,214           |             |             | 20.3        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Restructuring (Note 12)                               |            | 68                         |            |                 | 0.3        |                   |            | 69              |             |             | 0.4         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Earnings before provision for taxes on income         |            | 4,401                      |            |                 | 20.9       |                   |            | 1,647           |             |             | 7.9         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Provision for (benefit from) taxes on income (Note 5) |            | 847                        |            |                 | 4.0        |                   |            | (106)           |             |             | (0.6)       |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| NET EARNINGS                                          |            | $                          | 3,554      |                 |            | 16.9              | %          |                 | $           | 1,753       |             |             | 8.5         | %           |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                       |            |                            |            |                 |            |                   |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| NET EARNINGS PER SHARE (Note 8)                       |            |                            |            |                 |            |                   |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Basic                                                 |            | $                          | 1.35       |                 |            |                   |            | $               | 0.67        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Diluted                                               |            | $                          | 1.33       |                 |            |                   |            | $               | 0.66        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                       |            |                            |            |                 |            |                   |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| AVG. SHARES OUTSTANDING                               |            |                            |            |                 |            |                   |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Basic                                                 |            | 2,632.5                    |            |                 |            |                   | 2,635.2    |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Diluted                                               |            | 2,669.3                    |            |                 |            |                   | 2,669.9    |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |

---

English News:
The Janssen Pharmaceutical Companies of Johnson & Johnson announcedtoday it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a common procedure in which blood flow is restored to the legs and feet due to symptomatic PAD. The application is based on data from the VOYAGER PAD study, which showed XARELTO (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major cardiovascular (CV) and limb events, with similar rates of Thrombolysis In Myocardial Infarction (TIMI) major bleeding. CLICK TO TWEET: @JanssenUS announces sNDA submission to @US_FDA in #peripheralarterydisease #PAD. Learn more: https://bit.ly/3koBvL3. \"Various antithrombotic regimens have been evaluated for short- and long-term prevention of major vascular events in patients with PAD, but only rivaroxaban in combination with aspirin has demonstrated a significant benefit over aspirin alone,\" said James List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular & Metabolism, Janssen Research & Development, LLC. \"Data from the VOYAGER PAD trial were the first in 20 years to show clinical benefit with an antithrombotic therapy in the symptomatic PAD population after lower-extremity revascularization, which speaks to the need for a new treatment in this space. We look forward to discussing these data with the FDA.\" Janssen and its development partner Bayer have conducted two major Phase 3 trials, VOYAGER PAD and COMPASS, that evaluated the use of dual antithrombotic pathway inhibition with XARELTO plus aspirin in patients with PAD. XARELTO, in combination with aspirin, was approved by the FDA in 2018 to reduce the risk of major CV events in patients with chronic PAD and coronary artery disease (CAD) the only direct oral anticoagulant (DOAC) approved for use in these populations. PAD is a serious underlying health crisis that impacts an estimated 20 million Americans, with only 8.5 million diagnosed.i,ii PAD also increases the risk for major CV events and is the leading cause of amputation,iii which can double a patient's risk of death.iv About VOYAGER PADThe Phase 3 VOYAGER PAD study included 6,564 patients from 542 sites across 34 countries worldwide. Patients were randomized in a 1:1 ratio and received either XARELTO(2.5 mg twice daily) plus aspirin (100 mg once daily) (n=3,286) or aspirin alone (100 mg once daily) (n=3,278). Patients were stratified by revascularization procedure type (endovascular vs. surgical) and use of clopidogrel, which was limited and administered based on the treating physician's discretion. Patients were followed for a median duration of 28 months. The primary efficacy endpoint was a composite of major adverse limb and CV events, including acute limb ischemia, major amputation for vascular causes, heart attack (myocardial infarction), ischemic stroke, or death from CV causes. The principal safety endpoint was major bleeding according to the TIMI classification. Eligible patients were at least 50 years old and had documented symptomatic lower-extremity PAD. Patients were eligible after a successful revascularization for symptomatic PAD within the last 10 days. Approximately two-thirds were treated with an endovascular procedure (65%) and one-third treated surgically (35%). Patients were excluded if they were clinically unstable, at heightened bleeding risk, or needed prohibited concomitant medications, including long-term clopidogrel. The median age was 67 years and 26% were women. Common risk factors for PAD included diabetes, an estimated glomerular filtration rate less than 60 mL/min/1.73 m2 (indicating mild-to-moderate kidney disease) and current smokers. WHAT IS XARELTO(rivaroxaban)? XARELTOis a prescription medicine used to: reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE) reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months help prevent a blood clot in the legs and lungs of people who have just had hip or knee replacement surgery help prevent blood clots in certain people hospitalized for an acute illness and after discharge, who are at risk of getting blood clots because of the loss of or decreased ability to move around (mobility) and other risks for getting blood clots, and who do not have a high risk of bleeding XARELTO is used with low dose aspirin to: reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) It is not known if XARELTOis safe and effective in children. IMPORTANT SAFETY INFORMATION WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO? XARELTO may cause serious side effects, including: Increased risk of blood clots if you stop taking XARELTO. People with atrial fibrillation (an irregular heart beat) that is not caused by a heart valve problem (nonvalvular) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO, you may have increased risk of forming a clot in your blood.Do not stop taking XARELTOwithout talking to the doctor who prescribes it for you. Stopping XARELTOincreases your risk of having a stroke.If you have to stop taking XARELTO, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming. Increased risk of bleeding. XARELTO can cause bleeding which can be serious, and may lead to death. This is because XARELTO is a blood thinner medicine (anticoagulant) that lowers blood clotting. During treatment with XARELTO you are likely to bruise more easily, and it may take longer for bleeding to stop. You may be at higher risk of bleeding if you take XARELTO and have certain other medical problems.You may have a higher risk of bleeding if you take XARELTO and take other medicines that increase your risk of bleeding, including: Aspirin or aspirin-containing products Long-term (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs) Warfarin sodium (Coumadin, Jantoven) Any medicine that contains heparin Clopidogrel (Plavix) Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) Other medicines to prevent or treat blood clots Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above. Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding: Unexpected bleeding or bleeding that lasts a long time, such as: Nosebleeds that happen often Unusual bleeding from gums Menstrual bleeding that is heavier than normal, or vaginal bleeding Bleeding that is severe or you cannot control Red, pink, or brown urine Bright red or black stools (looks like tar) Cough up blood or blood clots Vomit blood or your vomit looks like \"coffee grounds\" Headaches, feeling dizzy or weak Pain, swelling, or new drainage at wound sites Spinal or epidural blood clots (hematoma). People who take a blood thinner medicine (anticoagulant) like XARELTO, and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if: A thin tube called an epidural catheter is placed in your back to give you certain medicine You take NSAIDs or a medicine to prevent blood from clotting You have a history of difficult or repeated epidural or spinal punctures You have a history of problems with your spine or have had surgery on your spine If you take XARELTO and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence). XARELTO is not for use in people with artificial heart valves. XARELTO is not for use in people with antiphospholipid syndrome (APS), especially with positive triple antibody testing. Do not take XARELTO if you: Currently have certain types of abnormal bleeding. Talk to your doctor before taking XARELTO if you currently have unusual bleeding. Are allergic to rivaroxaban or any of the ingredients of XARELTO. Before taking XARELTO, tell your doctor about all your medical conditions, including if you: Have ever had bleeding problems Have liver or kidney problems Have antiphospholipid syndrome (APS) Are pregnant or plan to become pregnant. It is not known if XARELTO will harm your unborn baby. Tell your doctor right away if you become pregnant during treatment with XARELTO. Taking XARELTO while you are pregnant may increase the risk of bleeding in you or in your unborn baby. If you take XARELTO during pregnancy, tell your doctor right away if you have any signs or symptoms of bleeding or blood loss. See \"What is the most important information I should know about XARELTO?\" for signs and symptoms of bleeding. Are breastfeeding or plan to breastfeed. XARELTO may pass into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with XARELTO. Tell all of your doctors and dentists that you are taking XARELTO. They should talk to the doctor who prescribed XARELTO for you before you have any surgery, medical or dental procedure. Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some of your other medicines may affect the way XARELTO works, causing side effects. Certain medicines may increase your risk of bleeding. See \"What is the most important information I should know about XARELTO?\" HOW SHOULD I TAKE XARELTO? Take XARELTO exactly as prescribed by your doctor. Do not change your dose or stop taking XARELTO unless your doctor tells you to. Your doctor may change your dose if needed. Your doctor will decide how long you should take XARELTO. XARELTO may need to be stopped for one or more days before any surgery or medical or dental procedure. Your doctor will tell you when to stop taking XARELTO and when to start taking XARELTO again after your surgery or procedure. If you need to stop taking XARELTO for any reason, talk to the doctor who prescribed XARELTO to you to find out when you should stop taking it. Do not stop taking XARELTO without first talking to the doctor who prescribes it to you. If you have difficulty swallowing XARELTO tablets whole, talk to your doctor about other ways to take XARELTO. Do not run out of XARELTO. Refill your prescription of XARELTO before you run out. When leaving the hospital following a hip or knee replacement, be sure that you will have XARELTO available to avoid missing any doses. If you take too much XARELTO, go to the nearest hospital emergency room or call your doctor right away. If you take XARELTO for: Atrial Fibrillation that is not caused by a heart valve problem: Take XARELTO 1 time a day with your evening meal. If you miss a dose of XARELTO, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. Blood clots in the veins of your legs or lungs: Take XARELTO 1 or 2 times a day as prescribed by your doctor. For the 10-mg dose, XARELTO may be taken with or without food. For the 15-mg and 20-mg doses, take XARELTO with food at the same time each day. If you miss a dose: If you take the 15-mg dose of XARELTO 2 times a day (a total of 30 mg of XARELTO in 1 day): Take XARELTO as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time. If you take XARELTO 1 time a day: Take XARELTO as soon as you remember on the same day. Take your next dose at your regularly scheduled time. Hip or knee replacement surgery: Take XARELTO 1 time a day with or without food. If you miss a dose of XARELTO, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. Blood clots in people hospitalized for an acute illness: Take XARELTO 1 time a day, with or without food, while you are in the hospital and after you are discharged as prescribed by your doctor. If you miss a dose of XARELTO, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. Reducing the risk of serious heart problems, heart attack and stroke in coronary artery disease or peripheral artery disease: Take XARELTO 2.5 mg 2 times a day with or without food. If you miss a dose of XARELTO, take your next dose at your regularly scheduled time. Take aspirin 75 to 100 mg once daily as instructed by your doctor. WHAT ARE THE POSSIBLE SIDE EFFECTS OF XARELTO? XARELTO may cause serious side effects: See \"What is the most important information I should know about XARELTO?\" The most common side effect of XARELTOwas bleeding. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736). Please read full Prescribing Information, including Boxed Warnings, and Medication Guidefor XARELTO. Trademarks are those of their respective owners. Janssen and Bayer together are developing rivaroxaban. About Janssen Cardiovascular & Metabolism In Cardiovascular & Metabolism (CVM), we take on the most pervasive diseases that burden hundreds of millions of people and healthcare systems around the world. As part of this long-standing commitment and propelled by our successes in treating type 2 diabetes and thrombosis, we advance highly differentiated therapies that prevent and treat life-threatening cardiovascular, metabolic and retinal diseases. Uncovering new therapies that can improve the quality of life for this large segment of the population is an important endeavor one which Janssen CVM will continue to lead in the years to come. Our mission is global, local and personal. Together, we can reshape the future of cardiovascular, metabolic and retinal disease prevention and treatment. Please visit www.janssen.com/cardiovascular-and-metabolism. About the Janssen Pharmaceutical Companies of Johnson & JohnsonAt Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenUSand https://twitter.com/JanssenGlobal. Janssen Research & Development, LLC, is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Cautions Concerning Forward-Looking Statements This press release contains \"forward-looking statements\" as defined in the Private Securities Litigation Reform Act of 1995 regarding rivaroxaban. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned \"Cautionary Note Regarding Forward-Looking Statements\" and \"Item 1A. Risk Factors,\" and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.comor on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. iRacial Disparities in Vascular Care. (n.d.). Retrieved October 2, 2020, from https://cardiovascularcoalition.com/our-patients/racial-disparities-in-vascular-care/ iiCenters for Disease Control and Prevention. Peripheral Arterial Disease Fact Sheet/Data & Statistics. Retrieved March 20, 2020 from: https://www.cdc.gov/heartdisease/pad.htm. iiiNorgren L, Hiatt WR, Dormandy JA, Hirsch AT, et al. The next 10 years in the management of peripheral artery disease: perspectives from the 'PAD 2009' Conference. Eur Vasc Endovasc Surg. 2010;40(3):375-380.ivJones WS, Patel MR, Dai D, et al. High mortality risks after major lower extremity amputation in Medicare patients with peripheral artery disease. Am Heart J. 2013;165(5):809-815. Mediacontacts: Joy-Lee PasqualoniMobile: (917) 547-8078[emailprotected] Jennifer SilventMobile: (973) 479-9845[emailprotected] Investorcontacts:Johnson & JohnsonChristopher DelOreficeOffice: (732) 524-2955 Jennifer McIntyreOffice: (732) 524-3922 SOURCE Janssen Pharmaceutical Companies of Johnson & Johnson

Chinese News:
全球新冠疫苗昨夜传出三大利好。福奇称2021年初之后的几个月疫苗能广泛使用；阿斯利康在全球范围内恢复新冠疫苗实验室试验；强生预计将于周一或周二重启疫苗试验。而海外疫情形势依然十分严峻，世卫组织称全球疫情正处于紧要关头，太多国家的病例数量呈指数级增长。美国累计确诊病例已经超过846万，单日确诊数也即将逼近最高纪录，而特朗普却被爆出已经几个月没有参加白宫新冠工作组的会议。比尔盖茨也警示称，即使一年后，世界仍不会恢复正常。疫情和刺激计划僵局的影响下，美股昨夜涨跌不一，结束周线三连涨走势。福奇：2021年初之后的几个月疫苗能广泛使用美国新冠病例激增，特朗普却缺席白宫新冠工作组会议很久昨夜，美国新冠疫苗时间表又传来好消息。美国国家过敏症和传染病研究所所长福奇表示，预计疫苗将在2021年初之后的几个月广泛使用。此前，当地时间本月14日，福奇称普通美国人要到2021年4月才有可能接种新冠疫苗。福奇称，新冠疫苗看起来很有希望。但福奇还表示，对当前的新冠肺炎感染率表示担忧，担心美国新冠病例激增。近日，福奇在接受采访时还提到，“随着人们进入低温的秋月和寒冷的冬月，如果情形不能逆转和变化，就会面临前所未遇的真正更为严重的一些问题。我们真的想躲得过去。”据约翰斯·霍普金斯大学数据，10月22日美国单日新增确诊病例76195例，已逼近7月16日单日新增病例77299例的最高纪录。截至美国东部时间10月23日17时(北京时间24日5时)，美国新冠肺炎确诊病例数超过846万例，达8468802例，死亡病例为223730例。而在单日确诊即将逼近最高纪录的关键时刻，白宫新冠工作组的会议却要减少到每周一次，福奇还表示，特朗普已经几个月没有参加工作组会议了。阿斯利康恢复新冠疫苗实验室试验 强生也快了美东时间本周五，阿斯利康方面表示：阿斯利康和牛津大学共同合作的新冠肺炎疫苗AZD1222实验室试验，在美国、英国、巴西、南非和日本监管机构确认安全的情况下已经恢复进行。美国食品药品监管局审查了全球试验的所有安全数据，授权恢复三期试验。据悉，美国食品药品管理局(FDA)已经结束了对两例候选疫苗可能引起神经系统副作用的调查，并于周五下午告知阿斯利康，该公司可以继续其新冠病毒候选疫苗在美国的试验。FDA得出结论认为，疫苗不是引起神经系统副作用的原因，尽管也不能排除联系。消息发布后，阿斯利康股价短线拉升，一度上涨0.84%，收盘微涨0.08%。据英国金融时报，疫苗协议令阿斯利康可以获得超过成本20%的利润。本月21日，多家外媒报道，巴西国家卫生监督局称，一名参加牛津与阿斯利康(AZN.US)合作研发新冠疫苗临床试验的28岁巴西志愿者死亡，但依然允许试验继续进行。值得注意的是，彭博社10月21日援引一位知情人士的消息称，这名死亡的志愿者没有注射疫苗。对此，阿斯利康中国方面回应称，“由于我们严格遵守医学保密性和临床试验法规，无法对正在进行新冠疫苗试验中的个别病例发表评论，我们可以确认已遵循所有必需的审查程序。”早在今年9月，阿斯利康在全球范围停止试验，因一名英国参与者患病。来自英国的这名受试者出现的副反应征状为“贯穿性脊髓炎”，这种炎症可以由病毒感染引起，严重时会导致脊髓发炎部分以下肢体的感觉神经、运动神经以及自主神经系统失控。随后，阿斯利康在英国、巴西、南非和印度恢复了研究，但在美国的临床试验并未恢复。美东时间本周五，华盛顿邮报报道称，强生的新冠疫苗试验也将很快恢复。当天不久后，强生表示，强生正与各国监管机构讨论恢复疫苗试验，将恢复新冠疫苗的第三阶段试验，预计将于周一或周二重启疫苗试验。强生还预计，美国新冠疫苗试验疗效数据将在2020年底或2021年初公布。强生股价周五小幅上涨。比尔盖茨：即使一年后世界仍不会恢复正常据腾讯科技10月23日消息，微软联合创始人比尔·盖茨(Bill Gates)周五在访谈节目中预测，尽管全球在努力遏制新冠肺炎疫情的传播，但即使一年后，世界仍不会恢复正常。盖茨称，“可悲的是，随着我们进入秋季，病例和死亡人数将再次回升。这些数字之所以如此之高，部分原因是我们的反应非常糟糕。”但盖茨也认为，2021年秋季，美国的情况将大大改善。盖茨称，“许多服务业的工作可以重新到位，学校也可以回到原位。但在该期间内，我们也面临着风险。”世卫组织：太多国家的病例数量呈指数级增长 全球疫情正处于紧要关头据央视新闻，当地时间10月23日，世卫组织举行新冠肺炎例行发布会，世卫组织总干事谭德塞表示，全球疫情正处于紧要关头，尤其是北半球。接下来的几个月将非常艰难，一些国家正处在危险的轨道上。谭德塞强调，太多国家的病例数量呈指数级增长，导致医院和重症监护病房趋于或超过饱和，而现在仅仅是10月份。谭德塞敦促各国领导人立即采取行动，以防止出现更多不必要的死亡，避免基本医疗服务崩溃或学校再次关闭。刺激计划僵局持续 美股周线结束三连涨 虽有疫苗相关的利好消息释放，但刺激计划的僵局依然拖累了美股走势。当地时间本周五，美国众议院议长佩洛西表示，希望能再出台一份刺激法案。美国白宫新闻秘书麦克纳尼也称，“非常”有可能达成刺激协议。但当天不久后，美国财政部长史蒂文·姆努钦表示，众议院议长南希·佩洛西在努力达成协议，但双方的谈判仍然存在较大分歧。美国国家经济顾问库德洛也直言，刺激计划的谈判目前进展不是很快。美股盘后，美国国会众议院议长助理表示，议长佩洛西希望很快能与白宫达成刺激计划的协议。如果驴象两党在谈判上取得进展，议长佩洛西还将再次与财长姆努钦对话。在刺激计划缺乏进展的背景下，昨夜美股三大指数涨跌不一，标普收涨0.35%，本周累跌0.52%；纳指收涨0.37%，本周累跌1.06%；道指收跌0.1%，本周累跌0.94%。道指和标普500指数结束周线三连涨。

Japanese News:
米国の大手ヘルスケア企業、ジョンソン・エンド・ジョンソン（J&J）は13日、2020年通期の業績予測を引き上げることを発表した。この発表の前日には、同社が開発中の新型コロナウイルス向けワクチンの臨床試試験が、一時的に中断したことを明らかにしていた。 今回の新たな見通しによれば、調整後の1株当たり利益は7.95～8.05ドルとなり、従来の予想（7.75～7.95ドル）から上方修正された。また売上高の予測も引き上げられており、同社による2020年の業績予想の引き上げはこれが年内で2度目となった。 J&Jは12日夜、新型コロナワクチン候補の最終段階の臨床試験について、一人の被験者に原因が明らかでない疾患が確認されたため、試験を一時中断したと発表した。同社はワクチン開発競争の中でも特に規模が大きい最終治験段階にまで到達していたが、今回の中断によって、急速に進められているワクチン開発の安全性やスピードに対する懸念が市場に広がる可能性もある。 なお、第3四半期（7～9月）の売上高は210億8000万ドル（約2兆2245億円）で、市場の平均予測である201億8000万ドルを大きく上回った。これは、主にがん治療薬の「ダラザレックス」「イムブルビカ」および乾癬治療薬の「ステラーラ」の販売が好調だったためとされる。 一方で、パンデミックによる医療処置の延期やキャンセルの影響で、医療デバイス部門は厳しい業績となった。特に外科や整形外科関連、そしてコンタクトレンズ事業の売上が減少し、同部門の売上高は前年同期と比べて3.9％減の62億ドルにとどまった。ただ、同社は2021年にこの部門が大きく回復するとの見通しを示している。 また、J&Jに加えて同業のアボット・ラボラトリーズも、4～6月期の業績において市場の控えめな予測を上回ったことを示した。両社は、新型コロナウイルスの流行初期に手術が広範に中止されたことで医療機器の需要が低迷したが、その状況が徐々に改善しつつあるとの見方を示した。J&Jは通年の業績予測を上方修正し、一方のアボットは3ヶ月前に取り下げていた通期の業績見通しを再提示した。 エドワード・ジョーンズ証券のアナリスト、アシュティン・エバンス氏は、両社の業績に対して「コロナによる影響が最も深刻だったのは4～6月期である可能性が高い」と述べた。 特にアボットについては、新型コロナ関連の検査製品を迅速に市場投入したことが奏功し、この分野だけで4～6月期に6億1500万ドル（約660億円）の売上を計上。純売上高は73億3000万ドル、調整後1株利益は57セントで、いずれも市場予想を上回った。同社はさらに、通期の調整後の1株利益が最低でも3.25ドルに達するとの見通しを示している。

Spanish News:
La empresa farmacéutica estadounidense Johnson & Johnson anunció este martes una revisión al alza de sus proyecciones de ganancias anuales por segunda ocasión en 2020. Este anuncio llegó apenas un día después de comunicar la suspensión temporal de las pruebas clínicas de su vacuna experimental contra el coronavirus. La noticia sobre la interrupción de las pruebas generó preocupación entre los inversores, provocando una caída en el valor de las acciones de la compañía. El director financiero, Joseph Wolk, señaló que actualmente resulta difícil determinar la duración exacta de esta pausa, impuesta debido a la aparición de una enfermedad inexplicable en uno de los participantes del ensayo clínico. En declaraciones ofrecidas a CNBC, Wolk afirmó que la suspensión podría resolverse en pocos días, aunque no descartó un plazo mayor, dependiendo de cuándo obtengan más información al respecto. Asimismo, la farmacéutica convocará un comité independiente de seguridad y datos, encargado de evaluar tanto los procedimientos del ensayo clínico como las circunstancias específicas del participante afectado. Johnson & Johnson es el primer gran laboratorio estadounidense en reportar resultados correspondientes al tercer trimestre del año, lo cual podría influir en las expectativas hacia otras compañías farmacéuticas. En este período, las ventas de la farmacéutica aumentaron a 21.080 millones de dólares, frente a los 20.730 millones del mismo trimestre del año anterior, impulsadas especialmente por los resultados positivos de su división farmacéutica. Destacó el desempeño del medicamento contra el cáncer Darzalex, cuyas ventas experimentaron un incremento del 43,7%, alcanzando 1.100 millones de dólares. Igualmente, el fármaco Imbruvica, comercializado en conjunto con AbbVie Inc., así como Stelara—medicamento utilizado para el tratamiento de la enfermedad de Crohn—registraron aumentos de doble dígito, llegando respectivamente a 1.030 millones y 1.950 millones de dólares. Por otro lado, la unidad de dispositivos médicos sufrió un descenso del 3,6% en sus ingresos, reportando ventas por 6.150 millones de dólares, debido principalmente al aplazamiento continuo de procedimientos quirúrgicos no urgentes por parte de los pacientes hospitalizados, quienes buscan evitar posibles contagios del COVID-19. En cuanto a las previsiones para el cierre de 2020, Johnson & Johnson elevó su estimación de ganancias ajustadas a un rango de entre 7,95 y 8,05 dólares por acción, frente a la estimación anterior, situada entre 7,75 y 7,95 dólares por título. Respecto a los resultados trimestrales ajustados, la empresa obtuvo ganancias por acción de 2,20 dólares, superando así las expectativas promedio del mercado, que anticipaba utilidades trimestrales de 1,98 dólares por acción, según datos provistos por IBES de Refinitiv.

Greek News:
Κατά το τρίτο οικονομικό τρίμηνο που έληξε στις 27 Σεπτεμβρίου 2020, η Johnson & Johnson κατέγραψε μικτό κέρδος ύψους $ 14,11 δισεκατομμυρίων, παρουσιάζοντας οριακή αύξηση σε σύγκριση με τα $ 13,86 δισεκατομμύρια της αντίστοιχης περιόδου του 2019. Το περιθώριο μικτού κέρδους διατηρήθηκε σταθερό, στοιχείο που υποδηλώνει σταθερή αποδοτικότητα στο κόστος πωληθέντων. Παράλληλα, η εταιρία προχωρά σε μία ευρείας κλίμακας αναδιάρθρωση της Παγκόσμιας Εφοδιαστικής Αλυσίδας, με στόχο την ενίσχυση της ευελιξίας, τη μείωση της πολυπλοκότητας, τη βελτίωση της ανταγωνιστικότητας κόστους. Η στρατηγική αυτή συνοδεύεται από σημαντικές επενδύσεις και συνεργασίες που αναμένεται να ενισχύσουν τις δυνατότητες ανάπτυξης της εταιρείας. Στο πλαίσιο του προγράμματος, η Johnson & Johnson κατέγραψε πρό φόρων χρεώσεις $ 130 εκατομμυρίων το τρίτο τρίμηνο του 2020, και συνολικά $ 363 εκατομμύρια κατά τους πρώτους εννέα μήνες. Από την έναρξη της αναδιάρθρωσης, το συνολικό κόστος ανήλθε περίπου στα $ 1,2 δισεκατομμύρια, με την εταιρία να εκτιμά ότι οι συνολικές χρεώσεις θα κυμανθούν μεταξύ $ 1,9 και $ 2,3 δισεκατομμυρίων σε χρονικό διάστημα τετραετίας έως πενταετίας. Η εταιρία επίσης προσδοκεί την εξοικονόμιση κόστους προ φόρων μεταξύ $ 0,6 και $ 0,8 δισεκατομμυρίων κυρίως εώς το 2022.

Question:
What trends can be observed in the company’s revenue amount over the past few years? Please quote the piece(s) of news aligned with the finding(s), if any.

Answer:

Question: What trends can be observed in the company’s revenue amount over the past few years? Please quote the piece(s) of news aligned with the finding(s), if any.

Johnson & Johnson reported increased revenues of $21.1B in Q3 2020 compared to $20.7 in Q3 2019, continuing its upward trend in pharmaceutical sales. The growth was driven by strong performance in oncology and immunology products, despite pandemic-related challenges in other divisions.

News Evidence: 
“Las ventas… aumentaron a 21.080 millones de dólares, frente a los 20.730 millones del mismo trimestre del año anterior.”

Question: How does the company’s balance sheet reflect its financial health in terms of total amount of current assets and the ratio of total liability divided by total equity? Please provide only the final result(s); do not include any calculation steps. Please quote the piece(s) of news aligned with the finding(s), if any.

Johnson & Johnson reported total current assets of $57.6B and a liability-to-equity ratio of approximately 1.65, indicating a solid financial position.

News Evidence:
None

Question: Are there any significant changes or irregularities in the amount of operating, investing and financing cash flow? Please quote the piece(s) of news aligned with the finding(s), if any.

There were no irregularities in cash flows, but slight shifts were observed: operating cash flow rose from $17.0B to 15.2B; negative investing cash flow increase a lot from -$4.9B to -$12.9B, largely due to purchases of investments; financing cash flow improved from -$13.9B to -$476M, mainly due to decrease in stock repurchase and increase of proceeds from debts.

News Evidence:
None

Question: What is the company's R&D ratio (R&D divided by revenue)? Please provide only the final result(s); do not include any calculation steps. Please quote the piece(s) of news aligned with the finding(s), if any.

The company’s R&D ratio for Q3 2020 is approximately 0.14.

News Evidence:
None